Evidence map›Paper›PMID 29726397›Full record

ArticleJournal of clinical research in pediatric endocrinology2018

Under-recognized Hypoparathyroidism in Thalassemia

Hataitip Tangngam, Pat Mahachoklertwattana, Preamrudee Poomthavorn, Ampaiwan Chuansumrit, Nongnuch Sirachainan, La-or Chailurkit, Patcharin Khlairit

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical research in pediatric endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Hataitip TangngamMahidol University Faculty of Medicine, Ramathibodi Hospital, Department of Pediatrics, Bangkok, Thailand
Pat MahachoklertwattanaMahidol University Faculty of Medicine, Ramathibodi Hospital, Department of Pediatrics, Bangkok, ThailandORCID 0000-0002-5670-2963
Preamrudee PoomthavornMahidol University Faculty of Medicine, Ramathibodi Hospital, Department of Pediatrics, Bangkok, ThailandORCID 0000-0001-6161-6210
Ampaiwan ChuansumritMahidol University Faculty of Medicine, Ramathibodi Hospital, Department of Pediatrics, Bangkok, ThailandORCID 0000-0003-1230-1591
Nongnuch SirachainanMahidol University Faculty of Medicine, Ramathibodi Hospital, Department of Pediatrics, Bangkok, ThailandORCID 0000-0001-8039-5476
La-or ChailurkitMahidol University Faculty of Medicine, Ramathibodi Hospital, Department of Medicine, Bangkok, ThailandORCID 0000-0002-1603-979X
Patcharin KhlairitMahidol University Faculty of Medicine, Ramathibodi Hospital, Department of Pediatrics, Bangkok, ThailandORCID 0000-0002-7901-7707
Mahidol University · THRamathibodi Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Symptomatic hypoparathyroidism [symptomatic hypocalcemia without elevated serum parathyroid hormone (PTH)] in patients with thalassemia is relatively rare. Asymptomatic mild hypocalcemia without elevated PTH, which is considered hypoparathyroidism, may be more common but under-recognized. Methods: Sixty-six transfusion-dependent thalassemic patients and 28 healthy controls were enrolled. Serum calcium (Ca), phosphate (P), creatinine (Cr), albumin, intact PTH, 25-hydroxyvitamin D (25-OHD), plasma intact fibroblast growth factor-23 (FGF-23), urinary Ca, P and Cr were measured. Tubular reabsorption of P was calculated. Results: Thalassemic patients had significantly lower median serum Ca levels than the controls [8.7 (7.8-9.7) vs 9.6 (8.7-10.1) mg/dL, p<0.001]. Hypoparathyroidism was found in 25 of 66 (38%) patients. Symptomatic hypoparathyroidism was not encountered. Thalassemic patients also had significantly lower median plasma FGF-23 levels than the controls [35.7 (2.1-242.8) vs 53.2 (13.3-218.6) pg/mL, p=0.01]. In patients with hypoparathyroidism, median plasma FGF-23 level was significantly lower than that of normoparathyroid patients [34.8 (2.1-120.0) vs 43.1 (3.2-242.8) pg/mL, p=0.048]. However, serum P, Cr, intact PTH and 25-OHD levels were not significantly different in the two groups. Conclusion: Hypoparathyroidism was not uncommon in patients with transfusion-dependent thalassemia treated with suboptimal iron chelation. Plasma intact FGF-23 level in hypoparathyroid patients was lower than that of normoparathyroid patients.

Indexed as

AdolescentBlood TransfusionCalciumChildChild, PreschoolCreatinineFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHypoparathyroidismIron Chelating AgentsMaleParathyroid HormonePhosphatesThalassemia25-hydroxyvitamin DCalciumCreatinineFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsIron Chelating AgentsParathyroid HormonePhosphatesVitamin Dfibroblast growth factor-23hypocalcemiahypoparathyroidismiron overloadThalassemia

Identifiers

PMID29726397
PMCPMC6280323
OpenAlexW2801165572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.